Scholarlink

Objective <p>Abexinostat, an novel pan-histone deacetylase inhibitor, induces tumor apoptosis and demonstrates therapeutic potential in B cell non-Hodgkin lymphoma (NHL). This phase 1 study investigate the safety, pharmacokinetics (PK), and efficacy of abexinostat in Chinese patients with relapsed/refractory (r/r) B cell NHL.</p> Methods <p>Patients with r/r B cell NHL received abexinostat orally at escalating doses of 40&#xa0;mg twice daily (bis in die, BID), 60&#xa0;mg BID, and 80&#xa0;mg BID with a 4-h interval, for seven days followed by a 7-day drug-free interval. Patients took abexinostat once on 3&#xa0;days before day 1 (D-3) of the first cycle in single dose period. If no dose limiting toxicity (DLT) occurred from D-3 to C1D1, the continuous dose period was started from C1D1, abexinostat was given BID. The Primary endpoints were safety and PK.</p> Results <p>From April 13, 2020 to November 30, 2023, 12 r/r B cell NHL patients were enrolled, including 6 follicular lymphoma (FL), 5 diffuse large B cell lymphoma (DLBCL) and 1 mantle cell lymphoma (MCL). 11 patients received at least one dose abexinostat included in the safety set. No DLT were observed, 80&#xa0;mg BID was the recommended phase 2 dose (RP2D). Most treatment emergent adverse events (TEAEs) were grade 1 or 2, and grade 3 TEAEs included thrombocytopenia (2/11, 18.2%) and hypertriglyceridemia (3/11, 27.3%). The median time to maximum concentration (T<sub>max</sub>) was 0.5–1.0&#xa0;h and the median terminal elimination half-life (T<sub>1/2</sub>) was 2.56–8.31&#xa0;h. Ten patients were included in full analysis set. The objective response rate (ORR) was 40.0% (4/10, 95% CI: 12.2–73.8), including 1 complete response and 3 partial response. The ORR was 50.0% (3/6, 95% CI: 11.8–88.2) of FL patients. The median progression-free survival and duration of response of FL were 8.38&#xa0;months (95% CI: 1.05-NE) and 7.82&#xa0;months(95% CI: 7.33-NE), respectively. The OS was not reached.</p> Conclusions <p>Abexinostat showed favorable tolerability with no DLT in Chinese patients with r/r B cell NHL. The RP2D was 80&#xa0;mg BID. The plasma concentration was dose-proportional manner. The PK result demonstrated that BID “one week on, one week off” administration is reasonable. Promising anti-tumor activity were seen in these patients population. This result support further investigation.</p> Trial registration <p>ClinicalTrials.gov (NCT04024696). Date of registration: 18 July 2019.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Safety, pharmacokinetics, and efficacy of abexinostat, an novel histone deacetylase inhibitor, in Chinese patients with relapsed/refractory B cell non-Hodgkin lymphoma: a Phase 1 study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月30日

查看全文
  • Lin Gui,
  • Zucheng Xie,
  • Yan Qin,
  • Peng Liu,
  • Jianliang Yang,
  • Xinrui Chen,
  • Zhenyu Li,
  • Ran Tao,
  • Yuankai Shi

摘要

Objective

Abexinostat, an novel pan-histone deacetylase inhibitor, induces tumor apoptosis and demonstrates therapeutic potential in B cell non-Hodgkin lymphoma (NHL). This phase 1 study investigate the safety, pharmacokinetics (PK), and efficacy of abexinostat in Chinese patients with relapsed/refractory (r/r) B cell NHL.

Methods

Patients with r/r B cell NHL received abexinostat orally at escalating doses of 40 mg twice daily (bis in die, BID), 60 mg BID, and 80 mg BID with a 4-h interval, for seven days followed by a 7-day drug-free interval. Patients took abexinostat once on 3 days before day 1 (D-3) of the first cycle in single dose period. If no dose limiting toxicity (DLT) occurred from D-3 to C1D1, the continuous dose period was started from C1D1, abexinostat was given BID. The Primary endpoints were safety and PK.

Results

From April 13, 2020 to November 30, 2023, 12 r/r B cell NHL patients were enrolled, including 6 follicular lymphoma (FL), 5 diffuse large B cell lymphoma (DLBCL) and 1 mantle cell lymphoma (MCL). 11 patients received at least one dose abexinostat included in the safety set. No DLT were observed, 80 mg BID was the recommended phase 2 dose (RP2D). Most treatment emergent adverse events (TEAEs) were grade 1 or 2, and grade 3 TEAEs included thrombocytopenia (2/11, 18.2%) and hypertriglyceridemia (3/11, 27.3%). The median time to maximum concentration (Tmax) was 0.5–1.0 h and the median terminal elimination half-life (T1/2) was 2.56–8.31 h. Ten patients were included in full analysis set. The objective response rate (ORR) was 40.0% (4/10, 95% CI: 12.2–73.8), including 1 complete response and 3 partial response. The ORR was 50.0% (3/6, 95% CI: 11.8–88.2) of FL patients. The median progression-free survival and duration of response of FL were 8.38 months (95% CI: 1.05-NE) and 7.82 months(95% CI: 7.33-NE), respectively. The OS was not reached.

Conclusions

Abexinostat showed favorable tolerability with no DLT in Chinese patients with r/r B cell NHL. The RP2D was 80 mg BID. The plasma concentration was dose-proportional manner. The PK result demonstrated that BID “one week on, one week off” administration is reasonable. Promising anti-tumor activity were seen in these patients population. This result support further investigation.

Trial registration

ClinicalTrials.gov (NCT04024696). Date of registration: 18 July 2019.